The scientific report on the Kazakhstan screening results has been published in a widely distributed international cancer journal

Biohit Oyj October 17, 2013 at 6 p.m. local time (EET)

In collaboration with the Medical Center of the President’s affairs Administration of the Republic of Kazakhstan and Biohit Oyj, a population-based screening with the GastroPanel test was conducted in Astana (2012-2013), of which the scientific report is now published in a widely distributed international cancer journal: Anticancer Research 2013;33(10).

Chief medical Director Kari Syrjänen, Biohit Oyj: ”The authors concluded that in countries like Kazakhstan where the annual incidence of gastric cancer (>20 cases per 100.000 inhabitants; vs. 8/100.000 in Finland) is alarmingly high, the GastroPanel test developed by Biohit Oyj should be the cost-effective diagnostic tool for large-scale, population-based screening of gastric cancer.”

Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K: Prevalence of H. pylori Infection and Atrophic Gastritis Among Symptomatic and Dyspeptic Adults in Kazakhstan. A Hospital-based Screening Study Using a Panel of Serum Biomarkers. Anticancer Res. 2013 Oct;33(10):4595-4602.

Abstract in PubMed database: www.ncbi.nlm.nih.gov/pubmed/24123036

Attachment: full article (pdf)

Attachment: Additional information about the GastroPanel examination (pdf)

Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com